Shanghai Yizhong Pharmaceutical Co., Ltd. (SHA:688091)
China · Delayed Price · Currency is CNY 40.11
-1.47 (-3.54%)
Jun 11, 2026, 3:00 PM CST
SHA:688091 Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | 68.54 | 64.56 | 6.98 | 161.55 | 142.85 | -4 |
Depreciation & Amortization | 11.99 | 11.99 | 11.16 | 7.88 | 6.43 | 6.59 |
Other Amortization | 2.1 | 2.1 | 0.7 | 0.3 | - | 0.56 |
Loss (Gain) From Sale of Investments | -7.17 | -7.17 | -9.69 | -7.52 | -12.89 | -5.44 |
Provision & Write-off of Bad Debts | 4.15 | 4.15 | -5.06 | 5.43 | 2.03 | 0.22 |
Other Operating Activities | 38.78 | -11.62 | -12.97 | -26.94 | -18.33 | -5.81 |
Change in Accounts Receivable | -81.94 | -81.94 | 85 | -69.19 | -28.46 | -21.5 |
Change in Inventory | -18.64 | -18.64 | -16.73 | -11.38 | -5.28 | -10.3 |
Change in Accounts Payable | 20.62 | 20.62 | -17.4 | 30.42 | 17.72 | -3.81 |
Operating Cash Flow | 35 | -19.38 | 39.44 | 86.55 | 110.78 | -48.78 |
Operating Cash Flow Growth | - | - | -54.44% | -21.87% | - | - |
Capital Expenditures | -146.27 | -130.09 | -80.04 | -8.78 | -35.88 | -3.14 |
Sale of Property, Plant & Equipment | - | - | 0 | - | - | - |
Investment in Securities | -450 | -450 | -135 | 86 | 511.29 | -788.74 |
Other Investing Activities | 142.01 | 6.43 | 22.39 | 39.27 | 26.86 | 6.25 |
Investing Cash Flow | -454.26 | -573.65 | -192.65 | 116.49 | 502.27 | -785.63 |
Short-Term Debt Issued | - | 25 | 9.1 | 44 | - | 16.75 |
Total Debt Issued | 25 | 25 | 9.1 | 44 | - | 16.75 |
Short-Term Debt Repaid | - | - | -53.1 | - | -16.75 | -3.25 |
Total Debt Repaid | - | - | -53.1 | - | -16.75 | -3.25 |
Net Debt Issued (Repaid) | 25 | 25 | -44 | 44 | -16.75 | 13.5 |
Issuance of Common Stock | - | 2.59 | 18.77 | - | - | 1,008 |
Repurchase of Common Stock | -35 | -35 | -37.24 | - | - | - |
Common Dividends Paid | -0.19 | -0.07 | -49.79 | -43.41 | -0.49 | - |
Other Financing Activities | - | - | - | - | - | -76.59 |
Financing Cash Flow | -10.18 | -7.48 | -112.27 | 0.59 | -17.24 | 944.65 |
Net Cash Flow | -429.45 | -600.52 | -265.48 | 203.64 | 595.82 | 110.24 |
Free Cash Flow | -111.27 | -149.47 | -40.6 | 77.77 | 74.9 | -51.93 |
Free Cash Flow Growth | - | - | - | 3.83% | - | - |
Free Cash Flow Margin | -34.32% | -47.29% | -23.40% | 21.59% | 31.74% | -1273.49% |
Free Cash Flow Per Share | -0.55 | -0.74 | -0.17 | 0.49 | 0.36 | -0.33 |
Cash Interest Paid | - | - | - | - | - | 0.59 |
Cash Income Tax Paid | 10.72 | 9.02 | 23.89 | 32.97 | -0.88 | 0.49 |
Levered Free Cash Flow | -168.26 | -167.25 | -30.3 | 55.22 | 33.72 | -50.68 |
Unlevered Free Cash Flow | -168.15 | -167.21 | -29.86 | 55.39 | 33.72 | -50.31 |
Change in Working Capital | -83.38 | -83.38 | 48.32 | -54.15 | -9.31 | -40.9 |